Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Explore this paper's citation graph
Summary
Therapeutic disruption of EGFR or ErbB2/neu protein function in vivo may result in partial suppression of angiogenesis, a feature that could enhance the therapeutic index of such agents in vivo and endow them with anti-tumor effects, the magnitude of which may be out of proportion with their observed cytostatic effects in monolayer tissue culture.
- Type
- article
- Published
- 1997-12-01
- Cited by
- 891
- References
- 0
- Access
- Open access
- OpenAlex
- https://openalex.org/W1804903119
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:10513439
Keywords
Angiogenesis, Cancer research, Vascular endothelial growth factor, Receptor tyrosine kinase, Epidermal growth factor
References
No references recorded for this paper.
Cited by
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents
- Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.
- Constitutive and inducible expression and regulation of vascular endothelial growth factor.
- Novel therapeutic targets in squamous cell carcinoma of the head and neck.
- Molecular therapy of head and neck cancer
- Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
- Prognostic value of thymidylate synthase, epidermal growth factor receptors and vascular endothelial growth factor in patients with stage III colon cancer.
- Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.
- VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab.
- Untersuchungen zum Einsatz von small interfering RNAs gegen epidermal growth factor receptor in humanen Gliomzellen
- The cardiac safety of trastuzumab in the treatment of breast cancer
- 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
- Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy.
- Zirconium-89 for positron emission tomography and hydroxamate resin column for gallium-68 generator
- Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.
- ErbB receptor tyrosine kinase inhibitors as therapeutic agents.
- Can tumor angiogenesis be inhibited without resistance?
- The molecular basis of the hypoxia response pathway: Tumour hypoxia as a therapy target
- Novel Functions of Cetuximab in EGFR-targeted Therapy: Radiosensitization, Glycolysis Inhibition, and Cellular Redox Status Regulation
- Targeting the Epidermal Growth Factor Receptor in the Treatment of Colorectal Cancer
Related papers
- Tumor Angiogenesis and Signal Transduction via Vascular Endothelial Growth Factor Receptor
- Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
- KDR activation in astrocytic neoplasms
- ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
- Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.
- AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
- How sensitive are epidermal growth factor receptor tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring epidermal growth factor receptor gene-sensitive mutations?
- Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action.
- Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade